Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of Single Ascending Doses of WCK 4873 in Healthy Volunteers
NCT03926962Phase 1Completed
- Sponsor
- Wockhardt
- Start
- Mar 2013
- Primary completion
- Jun 2013
- Modality
- RNA-Targeting Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in community-acquired bacterial pneumonia (CAP) comparing WCK 4873 with Placebo (2 arms). Primary endpoints: Treatment Emergent Adverse Events at Day 18 and Pharmacokinetic parameters at Day 4. Started Mar 2013; status: completed.
02
Drugs
nafithromycin
03
Conditions
community-acquired bacterial pneumonia (CAP)
Beyond the preview
Go deeper on NCT03926962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03926962.